The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|July 22, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-03-2016
- Volume 11
- Issue 8
Recipharm Expands Blow-Fill-Seal Capacity at France Facility
Author(s)Pharmaceutical Technology Editors
The company will invest €18 million in its Kaysersberg facility to expand blow-fill-seal capacity.
Advertisement
On July 5, 2016, Recipharm announced that the company will invest €18 million (approximately $19.73) to expand blow-fill-seal (BFS) capacity at its site in Kaysersberg, France. The investment will include the introduction of a BFS high-speed filling and packaging line, Recipharm said in a press announcement. Recihparm’s Kaysersberg site is a sterile facility specializing in BFS technology for sterile liquids.
Recipharm says it will also prepare to add three additional filling lines to the facility in upcoming years, increasing the company’s BFS capacity by 50%. Yves Buelens, general manager of the Kaysersberg site, said the company is experiencing increased demand for BFS services. “We are experiencing increased demand for our blow-fill-seal services from markets including the United States, Turkey, Australia, and Canada, and the new filling line will help us to meet this growing need,” Buelens noted in a press announcement.
Source: Recipharm
Articles in this issue
about 10 years ago
Slower Bio/Pharma Investment Could Hurt CDMOs in 2017about 10 years ago
Supply Chain Partner Scrutiny Moves Beyond GMPsabout 10 years ago
Chiral Advances Demonstrate Promise for API Synthesisabout 10 years ago
NIST Issues mAb Reference Standardabout 10 years ago
EMA Suspends Drugs Due to Flawed Bioequivalence Studiesabout 10 years ago
CordenPharma Expands into Oligonucleotide APIsabout 10 years ago
Shimadzu System Combines HPLC and UHPLC Methodsabout 10 years ago
Catalent to Commercially Supply Palatin FSD Pen Injectorsabout 10 years ago
Zenith Appoints Serialization DirectorAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement